source
- Summit Therapeutics' ivonescimab shows improved survival trend in extended follow-up, easing investor doubtsA new analysis of Summit Therapeutics and Akeso's dual‑acting cancer immunotherapy ivonescimab indicates that the drug's impact on overall survival has grown with longer observation. The extended d…
- Novartis beats sales expectations as Q2 revenue rises to $14.4B, eyes upcoming study readoutsNovartis reported a modest rise in second‑quarter sales, lifting its share price after the company posted a 1% increase in net sales to $14.4 billion, surpassing analyst forecasts for a decline. A…